40-301 : Special Drug Use-Results Survey of ADLUMIZ

JRCT ID: jRCT2011210014

Registered date:25/05/2021

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: Cancer cachexia: non-small cell lung cancer, gastric cancer, pancreatic cancer, large intestine canc
• Date of first enrollment: 23/04/2021
• Target sample size: 5000
• Study type: Observational

Outcome(s)

Primary Outcome

[Safety]Occurrence status of adverse drug reactions and infections, Occurrence status of adverse drug reactions corresponding to specified safety concerns, Factors that are considered to affect safety
Specified safety concerns: hyperglycemia, hepatic impairment, conduction disorders, and interactions with moderate CYP3A4 inhibitors
[Efficacy]Body weight increasing effect and appetite increasing effect

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both
• Include criteria: All patients with (Cancer cachexia: non-small cell lung cancer, gastric cancer, pancreatic cancer, large intestine cancer) for whom ADLUMIZ is administered
• Exclude criteria: patients who have not received ADLUMIZ

Related Information

• Primary Sponsor: Kuro Toshihiko